$ANEB
Anebulo Pharmaceuticals, Inc.

2022 Q3 Form 10-K Financial Statement

#000149315222025448 Filed on September 09, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.388M $1.207M $3.870M
YoY Change 65.3% 78.07% 187.97%
% of Gross Profit
Research & Development $1.224M $1.118M $2.962M
YoY Change 71.13% -38.11% 30.46%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $2.612M $2.325M $6.831M
YoY Change 67.99% -6.41% 89.03%
Operating Profit -$2.612M -$6.831M
YoY Change 67.99% 89.03%
Interest Expense $7.330K
YoY Change -100.03%
% of Operating Profit
Other Income/Expense, Net $210.00 -$4.590K $5.555K
YoY Change -86.27% 242.54% -514.55%
Pretax Income -$2.612M -$2.323M -$6.826M
YoY Change 68.14% -92.02% -77.44%
Income Tax
% Of Pretax Income
Net Earnings -$2.612M -$2.323M -$6.826M
YoY Change 68.14% -92.02% -77.44%
Net Earnings / Revenue
Basic Earnings Per Share -$0.11 -$0.29
Diluted Earnings Per Share -$111.5K -$99.50K -$292.4K
COMMON SHARES
Basic Shares Outstanding 23.37M shares 23.34M shares
Diluted Shares Outstanding 23.42M shares 23.34M shares

Balance Sheet

Concept 2022 Q3 2022 Q2 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $19.21M $14.55M $14.55M
YoY Change 0.03% -27.21% -27.21%
Cash & Equivalents $19.21M $14.55M
Short-Term Investments
Other Short-Term Assets $601.7K $1.031M $1.031M
YoY Change -53.45% -38.19% -38.19%
Inventory
Prepaid Expenses $601.7K $1.031M
Receivables
Other Receivables
Total Short-Term Assets $19.82M $15.58M $15.58M
YoY Change -3.34% -28.05% -28.05%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets -$5.00 $1.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $19.82M $15.58M $15.58M
Total Long-Term Assets -$5.00 $1.00 $0.00
Total Assets $19.82M $15.58M $15.58M
YoY Change -3.34% -28.05% -28.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $523.5K $380.8K $380.8K
YoY Change 6.0% 246.05% 246.05%
Accrued Expenses $174.7K $131.7K $131.7K
YoY Change 53.4% 0.09% 0.08%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $698.2K $512.5K $512.5K
YoY Change 14.89% 112.11% 112.11%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $698.2K $512.5K $512.5K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $698.2K $512.5K $512.5K
YoY Change 14.89% 112.11% 112.11%
SHAREHOLDERS EQUITY
Retained Earnings -$48.08M -$45.47M
YoY Change 17.66%
Common Stock $25.63K $23.35K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $19.12M $15.07M $15.07M
YoY Change
Total Liabilities & Shareholders Equity $19.82M $15.58M $15.58M
YoY Change -3.34% -28.05% -28.05%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022
OPERATING ACTIVITIES
Net Income -$2.612M -$2.323M -$6.826M
YoY Change 68.14% -92.02% -77.44%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$2.034M -$1.999M -$5.437M
YoY Change 161.46% -35.6% 11.62%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $6.699M 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -$2.034M -1.999M -$5.437M
Cash From Investing Activities
Cash From Financing Activities $6.699M 0.000
Net Change In Cash $4.665M -1.999M -$5.437M
YoY Change -699.72% -111.99% -132.06%
FREE CASH FLOW
Cash From Operating Activities -$2.034M -$1.999M -$5.437M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
usd
CY2022 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001815974
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2022 us-gaap Interest Expense
InterestExpense
usd
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
usd
CY2022 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
usd
CY2021 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
usd
CY2021 ANEB Stock Issued During Period Value Conversion Of Milestone Warrant Into Convertible Preferred Stock
StockIssuedDuringPeriodValueConversionOfMilestoneWarrantIntoConvertiblePreferredStock
usd
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
usd
CY2022 us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
usd
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
CY2022 us-gaap Payments For Repurchase Of Initial Public Offering
PaymentsForRepurchaseOfInitialPublicOffering
usd
CY2022 us-gaap Interest Paid Net
InterestPaidNet
usd
CY2022 us-gaap Stock Issued1
StockIssued1
usd
CY2022 ANEB Non Cash Deemed Dividend
NonCashDeemedDividend
usd
CY2022 ANEB Cashless Exercise Of Warrants Into Convertible Preferred Stock
CashlessExerciseOfWarrantsIntoConvertiblePreferredStock
usd
CY2020Q2 ANEB Warrant Liability
WarrantLiability
usd
CY2021Q2 ANEB Warrant Liability
WarrantLiability
usd
CY2021Q2 ANEB Accrued Paid Time Off Current
AccruedPaidTimeOffCurrent
usd
CY2022Q2 ANEB Accrued Legal Current
AccruedLegalCurrent
usd
CY2022 us-gaap Interest Expense
InterestExpense
usd
CY2022Q2 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
usd
CY2021Q2 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
usd
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
shares
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2020Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
shares
CY2020Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
shares
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-40388
CY2022 dei Entity Registrant Name
EntityRegistrantName
ANEBULO PHARMACEUTICALS, INC.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-1170950
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
1415 Ranch Road 620 South
CY2022 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 201
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Lakeway
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
78734
CY2022 dei City Area Code
CityAreaCode
(512)
CY2022 dei Local Phone Number
LocalPhoneNumber
598-0931
CY2022 dei Security12b Title
Security12bTitle
Common Stock
CY2022 dei Trading Symbol
TradingSymbol
ANEB
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Public Float
EntityPublicFloat
49681078 usd
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
23368567 shares
CY2022 dei Auditor Firm
AuditorFirmId
274
CY2022 dei Auditor Name
AuditorName
EISNERAMPER LLP
CY2022 dei Auditor Location
AuditorLocation
Iselin, New Jersey
CY2022Q2 us-gaap Cash
Cash
14548471 usd
CY2021Q2 us-gaap Cash
Cash
19985645 usd
CY2022Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1030960 usd
CY2021Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1667846 usd
CY2022Q2 us-gaap Assets
Assets
15579431 usd
CY2021Q2 us-gaap Assets
Assets
21653491 usd
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
380828 usd
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
110048 usd
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
131703 usd
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
131585 usd
CY2022Q2 us-gaap Liabilities
Liabilities
512531 usd
CY2021Q2 us-gaap Liabilities
Liabilities
241633 usd
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000 shares
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0 shares
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000 shares
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23344567 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23344567 shares
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23344567 shares
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23344567 shares
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
23345 usd
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
23345 usd
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
60513258 usd
CY2021Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
60032597 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-45469703 usd
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-38644084 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
15066900 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
21411858 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15579431 usd
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
21653491 usd
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2961538 usd
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2269998 usd
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3869636 usd
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1343755 usd
CY2022 us-gaap Operating Expenses
OperatingExpenses
6831174 usd
CY2021 us-gaap Operating Expenses
OperatingExpenses
3613753 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-6831174 usd
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-3613753 usd
CY2022 us-gaap Interest Income Other
InterestIncomeOther
7332 usd
CY2021 us-gaap Interest Income Other
InterestIncomeOther
1020 usd
CY2021 us-gaap Interest Expense
InterestExpense
11767 usd
CY2021 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
26626710 usd
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1777 usd
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1344 usd
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5555 usd
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-26638801 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-6825619 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-30252554 usd
CY2021 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
8208393 usd
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6825619 usd
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-38460947 usd
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23344567 shares
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13612701 shares
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.83
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-171137 usd
CY2021 us-gaap Dividends
Dividends
8208393 usd
CY2021 ANEB Stock Issued During Period Value Conversion Of Convertible Preferred Stock To Common Stock Upon Closing Of Initial Public Offering
StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering
40060855 usd
CY2021 ANEB Stock Issued During Period Value Issuance Of Common Stock From Initial Public Offering Net Of Issuance Costs
StockIssuedDuringPeriodValueIssuanceOfCommonStockFromInitialPublicOfferingNetOfIssuanceCosts
19783140 usd
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
199947 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-30252554 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
21411858 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
21411858 usd
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
480661 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-6825619 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
15066900 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
15066900 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-6825619 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-30252554 usd
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
480661 usd
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
199947 usd
CY2021 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
26626710 usd
CY2021 us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
-3500 usd
CY2022 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-636886 usd
CY2021 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1667846 usd
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
270780 usd
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
110048 usd
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
118 usd
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
109006 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5437174 usd
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4871189 usd
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
20604770 usd
CY2021 us-gaap Payments For Repurchase Of Initial Public Offering
PaymentsForRepurchaseOfInitialPublicOffering
821630 usd
CY2021 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
2250000 usd
CY2021 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
201286 usd
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
21831854 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5437174 usd
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
16960665 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
19985645 usd
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3024980 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
14548471 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
19985645 usd
CY2021 us-gaap Interest Paid Net
InterestPaidNet
13053 usd
CY2021 us-gaap Stock Issued1
StockIssued1
40060855 usd
CY2021 ANEB Non Cash Deemed Dividend
NonCashDeemedDividend
8208393 usd
CY2021 ANEB Cashless Exercise Of Warrants Into Convertible Preferred Stock
CashlessExerciseOfWarrantsIntoConvertiblePreferredStock
37085103 usd
CY2021Q2 us-gaap Stockholders Equity Note Stock Split
StockholdersEquityNoteStockSplit
six-for-one stock split
CY2021Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
21548000 usd
CY2021Q2 us-gaap Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
7283843 shares
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-6825619 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-45469703 usd
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_845_eus-gaap--UseOfEstimates_zrnwn6MnLzs9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zcK44YnqprIj">Use of estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the audited financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>
CY2022Q2 us-gaap Deferred Offering Costs
DeferredOfferingCosts
0 usd
CY2021Q2 us-gaap Deferred Offering Costs
DeferredOfferingCosts
0 usd
CY2022 us-gaap Payments For Rent
PaymentsForRent
14434 usd
CY2021 us-gaap Payments For Rent
PaymentsForRent
12629 usd
CY2021 ANEB Proceeds From Issuance Of Milestone Warrants
ProceedsFromIssuanceOfMilestoneWarrants
2250000 usd
CY2021 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
8208393 usd
CY2021 us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
26627000 usd
CY2021 ANEB Warrants Converted Into Convertible Preferred Upon Ipo
WarrantsConvertedIntoConvertiblePreferredUponIpo
37085000 usd
CY2021 ANEB Fair Value Of Warrants Issued To Investors
FairValueOfWarrantsIssuedToInvestors
10458000 usd
CY2021 us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
26627000 usd
CY2021 ANEB Fair Value Of Warrant Liability Prior To Ipo
FairValueOfWarrantLiabilityPriorToIpo
37085000 usd
CY2021 ANEB Warrants Converted Into Convertible Preferred Upon Ipo
WarrantsConvertedIntoConvertiblePreferredUponIpo
37085000 usd
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
480661 usd
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
199947 usd
CY2022Q2 ANEB Fair Value Liabilities Level1 To Level2 Transfers Amounts
FairValueLiabilitiesLevel1ToLevel2TransfersAmounts
0 usd
CY2021Q2 ANEB Fair Value Liabilities Level1 To Level2 Transfers Amounts
FairValueLiabilitiesLevel1ToLevel2TransfersAmounts
0 usd
CY2022Q2 ANEB Prepaid Research And Development
PrepaidResearchAndDevelopment
210865 usd
CY2021Q2 ANEB Prepaid Research And Development
PrepaidResearchAndDevelopment
544435 usd
CY2022Q2 us-gaap Prepaid Insurance
PrepaidInsurance
790343 usd
CY2021Q2 us-gaap Prepaid Insurance
PrepaidInsurance
1093101 usd
CY2022Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
29752 usd
CY2021Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
30310 usd
CY2022Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1030960 usd
CY2021Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1667846 usd
CY2022Q2 ANEB Accrued Research And Development
AccruedResearchAndDevelopment
105980 usd
CY2021Q2 ANEB Accrued Research And Development
AccruedResearchAndDevelopment
121662 usd
CY2022Q2 ANEB Accrued Paid Time Off Current
AccruedPaidTimeOffCurrent
25723 usd
CY2021Q2 ANEB Accrued Legal Current
AccruedLegalCurrent
9923 usd
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
131703 usd
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
131585 usd
CY2021 us-gaap Interest Expense
InterestExpense
11767 usd
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210 pure
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
0.000 pure
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
0.000 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.000 pure
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.185 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.210 pure
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.025 pure
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000 pure
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000 pure
CY2022Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
1843175 usd
CY2021Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
497171 usd
CY2022Q2 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
265741 usd
CY2021Q2 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
281137 usd
CY2022Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
120576 usd
CY2021Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
19644 usd
CY2022Q2 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
2229492 usd
CY2021Q2 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
797952 usd
CY2022Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
2229492 usd
CY2021Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
797952 usd
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
1431540 usd
CY2022Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
8777022 usd
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.50 pure
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.496 pure
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.509 pure
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0079 pure
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0297 pure
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0013 pure
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0064 pure
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
604404 shares
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.18
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1307055 shares
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.76
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1911459 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.63
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y4M24D
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2625173 usd
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
304914 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.55
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y8M12D
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
848665 usd
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
982500 shares
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.11
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
982500 shares
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
0.11
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
106437 usd
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1911459 shares
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
604404 shares

Files In Submission

Name View Source Status
ex3-2.htm Edgar Link pending
ex3-3.htm Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
0001493152-22-025448-index-headers.html Edgar Link pending
0001493152-22-025448-index.html Edgar Link pending
0001493152-22-025448.txt Edgar Link pending
0001493152-22-025448-xbrl.zip Edgar Link pending
aneb-20220630.xsd Edgar Link pending
ex10-2.htm Edgar Link pending
ex10-6.htm Edgar Link pending
ex10-8.htm Edgar Link pending
ex10-8_001.jpg Edgar Link pending
ex10-9.htm Edgar Link pending
ex23-1.htm Edgar Link pending
ex3-1.htm Edgar Link pending
aneb-20220630_pre.xml Edgar Link unprocessable
aneb-20220630_lab.xml Edgar Link unprocessable
ex32-2.htm Edgar Link pending
ex4-4.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-k.htm Edgar Link pending
form10-k_002.jpg Edgar Link pending
form10-k_003.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
form10-k_htm.xml Edgar Link completed
Show.js Edgar Link pending
aneb-20220630_cal.xml Edgar Link unprocessable
aneb-20220630_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable